Key result
Single-dose mRNA BNT162b2 vaccination after prior infection elicits sufficient antibodies despite post-heart transplant immunosuppression.
Why the study?
Adequate immune response to vaccination remains a challenge in patients after solid organ transplantation.
Does a single dose mRNA BNT 162b2 vaccination elicit an adequate immune response in a patient with prior SARS-CoV-2 infection undergoing rapid heart transplantation and immunosuppression?
Case Report (n=1)
Does a single dose mRNA BNT 162b2 vaccination elicit an adequate immune response in a patient with prior SARS-CoV-2 infection undergoing rapid heart transplantation and immunosuppression?
A single dose of mRNA SARS-CoV-2 vaccine may elicit an adequate antibody response in heart transplant recipients with prior infection, despite immunosuppression.
May support pre-transplant mRNA vaccination in LVAD patients; leaves open optimal timing and immunogenicity in heart transplant recipients.
Adequate immune response to vaccination remains a challenge in patients after solid organ transplantation. We report a case of a 61-year-old male patient who received a left ventricular assist device as a bridge to transplant therapy. Three months before transplantation, he suffered mild SARS-CoV-2 infection and was successfully discharged thereafter. Eight days before his successful heart transplantation, he received mRNA BNT 162b2 vaccination. Immediately after transplantation, we detected sufficient rise of nucleocapsid and spike antibodies despite immune suppression therapy. We suspect potential booster effects of the previous SARS-CoV-2 infection giving rise to adequate immune response following single vaccination.
No takes yet. Share an insight, caveat, or question.
Erbel‐Khurtsidze et al. (2021) conducted a case report in Heart transplantation and SARS-CoV-2 infection (n=1). mRNA BNT 162b2 vaccination after SARS-CoV-2 infection was evaluated on Rise of nucleocapsid and spike antibodies. A single dose of mRNA BNT 162b2 vaccination after prior SARS-CoV-2 infection elicited a sufficient rise in nucleocapsid and spike antibodies despite post-heart transplant immunosuppression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: